CORONA REMEDIES
Quarterly Results Analysis [Mar2026]
CORONA REMEDIES Quarterly Results
| Consolidated | Mar2026 UnAudited |
Dec2025 UnAudited |
Sep2025 UnAudited |
Mar2025 UnAudited |
Dec2024 UnAudited |
Sep2024 UnAudited |
|---|---|---|---|---|---|---|
| Revenues | ₹353 Cr | ₹342 Cr | ₹361 Cr | ₹294 Cr | ₹298 Cr | ₹314 Cr |
| Expenses | ₹291 Cr | ₹259 Cr | ₹283 Cr | ₹239 Cr | ₹228 Cr | ₹247 Cr |
| Operating Income | ₹62 Cr | ₹83 Cr | ₹78 Cr | ₹54 Cr | ₹69 Cr | ₹67 Cr |
| Other Income | ₹4 Cr | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹1 Cr | ₹2 Cr |
| Interest | ₹1 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹3 Cr |
| Depreciation | ₹10 Cr | ₹9 Cr | ₹9 Cr | ₹10 Cr | ₹10 Cr | ₹9 Cr |
| Profit Before Tax | ₹54 Cr | ₹55 Cr | ₹70 Cr | ₹43 Cr | ₹58 Cr | ₹57 Cr |
| Profit After Tax | ₹45 Cr | ₹41 Cr | ₹52 Cr | ₹31 Cr | ₹45 Cr | ₹43 Cr |
| EPS | ₹7.41 | ₹6.75 | ₹8.55 | ₹5.16 | ₹7.35 | ₹7.03 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| CORONA REMEDIES | 1.4% | 11.3% | NA |
| SUN PHARMACEUTICAL INDUSTRIES | 1.4% | 1.2% | 13.8% |
| DIVIS LABORATORIES | -0.5% | -0.6% | 4% |
| TORRENT PHARMACEUTICALS | 2.1% | 1.5% | 42.2% |
| CIPLA | 6.4% | 1.6% | -3.1% |
| DR REDDYS LABORATORIES | 6.2% | 1.6% | 0.2% |
| MANKIND PHARMA | 1.8% | 1.8% | 6.6% |
| LUPIN | -0.4% | 3.5% | 22.5% |
| ZYDUS LIFESCIENCES | 2.9% | 2.1% | 15.7% |
CORONA REMEDIES Quarterly Revenues
| Revenues | |
|---|---|
| Q-o-Q | 3.12 % |
| Y-o-Y | 18.61 % |
| Quarters | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹353 Cr | 3.12 | |
| Dec2025 | ₹342 Cr | -5.18 | |
| Sep2025 | ₹361 Cr | 22.96 | |
| Mar2025 | ₹294 Cr | -1.34 | |
| Dec2024 | ₹298 Cr | -5.16 | |
| Sep2024 | ₹314 Cr | - | |
CORONA REMEDIES Quarterly Operating Profit
| Operating Profit | |
|---|---|
| Q-o-Q | -25.42 % |
| Y-o-Y | -10.66 % |
| Quarters | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹62 Cr | -25.42 | |
| Dec2025 | ₹83 Cr | 5.98 | |
| Sep2025 | ₹78 Cr | 44.73 | |
| Mar2025 | ₹54 Cr | -21.90 | |
| Dec2024 | ₹69 Cr | 3.89 | |
| Sep2024 | ₹67 Cr | - | |
| Operating Margins | |
|---|---|
| Q-o-Q | -27.71 % |
| Y-o-Y | -24.70 % |
| Quarters | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 17.56% | -27.71 | |
| Dec2025 | 24.29% | 11.78 | |
| Sep2025 | 21.73% | 17.71 | |
| Mar2025 | 18.46% | -20.84 | |
| Dec2024 | 23.32% | 9.53 | |
| Sep2024 | 21.29% | - | |
CORONA REMEDIES Quarterly Profit After Tax
| Profit After Tax(PAT) | |
|---|---|
| Q-o-Q | 9.21 % |
| Y-o-Y | 0.63 % |
| Quarters | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹45 Cr | 9.21 | |
| Dec2025 | ₹41 Cr | -20.90 | |
| Sep2025 | ₹52 Cr | 66.40 | |
| Mar2025 | ₹31 Cr | -30.00 | |
| Dec2024 | ₹45 Cr | 4.16 | |
| Sep2024 | ₹43 Cr | - | |
| PAT Margins | |
|---|---|
| Q-o-Q | 5.89 % |
| Y-o-Y | -15.16 % |
| Quarters | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 12.76 % | 5.89 | |
| Dec2025 | 12.05 % | -16.55 | |
| Sep2025 | 14.44 % | 35.33 | |
| Mar2025 | 10.67 % | -29.06 | |
| Dec2024 | 15.04 % | 9.86 | |
| Sep2024 | 13.69 % | - | |
CORONA REMEDIES Quarterly Earnings Per Share (EPS)
| EPS | |
|---|---|
| Q-o-Q | 9.78 % |
| Y-o-Y | 0.82 % |
| Quarters | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹7.41 | 9.78 | |
| Dec2025 | ₹6.75 | -21.05 | |
| Sep2025 | ₹8.55 | 65.70 | |
| Mar2025 | ₹5.16 | -29.80 | |
| Dec2024 | ₹7.35 | 4.55 | |
| Sep2024 | ₹7.03 | - | |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs MANKIND PHARMA LTD